,i  #aag? ,,congress  #a/ ,session  ,h4 
,r4 #egde  ,,9 ,,! ,,h\se ,,(           
,,repres5tatives  ,octob] #bg1 #bjba,mr4
 ,dunn 7= himself & ,mr4 ,jackson7      
introduc$ ! foll[+ bill2 :i* 0 ref]r$ to
 ! ,committee on ,en]gy & ,comm]ce1 & 9 
addition to ! ,committee on ,ways &     
,means1 = a p]iod to be subsequ5tly     
det]m9$ by ! ,speak]1 9 ea* case =      
consid]ation ( su* provisions z fall )9 
! jurisdiction ( ! committee conc]n$  ,a
 ,,bill  ,to cl>ify ,m$ic>e cov]age =   
,,covid-#ai te/+ & to provide support = 
cellul> immune response rese>* =        
,,covid-#ai1 & = o!r purposes4  #a4     
,%ort title ,?is ,act may be cit$ z !   
,,covid-#ai ,access to ,te/+ & ,support 
= ,immune ,response ,rese>* ,act (      
#bjba4  #b4 ,f9d+s ,congress f9ds !     
foll[+3 7#a7 ,a public heal? em]g5cy    
reg>d+ ! ,,covid-#ai p&emic 0 fir/      
decl>$ on ,janu>y #ca1 #bjbj1 & has be5 
subsequ5tly r5ew$ repeat$ly1 mo/ rec5tly
 on ,july #ai1 #bjba1 by ! ,secret>y (  
,heal? & ,human ,s]vices "u bo?         

,republican & ,democratic adm9i/rations4
  7#b7 ,9 ! spr+ ( #bjbj1 ! only te/s   
available to det]m9e :e!r a p]son _h a  
rec5t or prior infection (              
,,s>s-,co,v-#b 7 s]ology te/s :i* c\ld  
id5tify :e!r a p]son _h antibodies      
specific to ! ,,s>s-,co,v-#b virus4     
7#c7 ,on ,may #h1 #bjbj1 ! ,c5t]s =     
,m$ic>e  ,m$icaid ,s]vices 7,,cms71 cit+
 ! ongo+ ,,covid-#ai public heal?       
em]g5cy1 issu$ an int]im f9al rule :i*  
recogniz$ on an int]im basis t c]ta9    
,food & ,drug ,adm9i/ration-au?oriz$    
s]ology te/s fall "u ! ,m$ic>e b5efit   
category = diagno/ic laboratory te/s4   
7#d7 ,on ,m>* #e1 #bjba1 ! ,food & ,drug
 ,adm9i/ration issu$ ! fir/ au?orization
 = ! em]g5cy use ( a cellul> 7,t-cell7  
immune response ,,covid-#ai te/ int5d$ =
 use z an aid 9 id5tify+ individuals )  
an adaptive ,t-cell immune response to  
,,s>s-,co,v-#b1 indicat+ rec5t or prior 
infection ) ,,s>s-,co,v-#b4  7#e7 ,,cms 
has yet to update its ,may #h1 #bjbj1   
int]im f9al rule or provide sep>ate     

guidance to cl>ify t ,m$ic>e cov]age    
ext5ds to o!r ,food & ,drug             
,adm9i/ration-au?oriz$ te/s1 includ+    
,t-cell te/s1 t are int5d$ = diagnos+   
rec5t or prior infection )              
,,s>s-,co,v-#b4  7#f7 ,9 rese>* &       
developm5t relat$ to infecti\s diseases 
& vacc9es1 includ+ ,,s>s-,co,v-#b1      
hi/orically ! antibody response1 :i* is 
only half ( ! adaptive immune sy/em1 has
 be5 ! prim>y tool = assessm5t4  7#g7 ,!
 o!r half ( ! adaptive immune response1 
! ,t-cell response1 has hi/orically be5 
m difficult to assess1 b sci5tific &    
te*nological advances n[ all[ = /&>diz$ 
& s5sitive me?ods to measure ,t-cells4  
7#h7 ,! ,national ,in/itutes ( ,heal? h 
integrat$ ,t-cell te/+ into c]ta9 /udies
 reg>d+ ! impact ( ,t-cells 9 detect+ & 
def5d+ aga9/ ,,s>s-,co,v-#b v>iants1 &  
!re exi/ additional rese>* opportunities
 reg>d+ ! cellul> immune response to    
,,s>s-,co,v-#b1 includ+-- 7,a7 id5tify+ 
! type & duration ( ,t-cell response t  
conf]s immunity 7includ+ to v>iants7    

foll[+ natural infection1 vacc9ation1 or
 bo?2  7,b7 und]/&+ ! ,t-cell response 9
 diff]5t populations1 includ+ *ildr51 ! 
eld]ly1 & immunocompromis$ individuals2 
&  7,c7 und]/&+ ! ,t-cell response 9    
pati5ts fac+ long-t]m ,,covid-#ai       
symptoms4  7#i7 ,evid5ce %[s ,t-cells   
play an important role 9 ! immune       
response to ,,covid-#ai & po9ts to ! ne$
 = a conc]t$ rese>* ef=t1 :i* c\ld h    
pr(\nd consequ5ces on public heal?1 su* 
z policies on boo/]s or ! developm5t (  
!rapeutics = pati5ts suff]+ f po/-acute 
sequelae ( ,,covid-#ai infection4  #c4  
,cl>ify+ ,m$ic>e cov]age ( ,,covid-#ai  
diagno/ic laboratory te/s  7a7 ,9 g5]al 
,! ,adm9i/rator ( ! ,c5t]s = ,m$ic>e    
,m$icaid ,s]vices %all by int]im rule1  
subregulatory guidance1 or o!rwise1     
provide = cov]age ( ,t-cell diagno/ic   
laboratory te/s furni%$ dur+ ! p]iod    
beg9n+ on ,janu>y #a1 #bjbb1 & end+ on !
 la/ date ( ! public heal? em]g5cy p]iod
 7describ$ 9 section #aace7;g77#a77;,b7 
( ! ,social ,security ,act 7#db         

,u4,s4,c4 #acbj;b-#e7;g77#a77;,b777 =   
b5efici>ies ) curr5t or kn[n prior      
,,covid-#ai infection or suspect$ curr5t
 or suspect$ pa/ ,,covid-#ai infection4 
7b7 ,t-,cell diagno/ic laboratory te/   
def9$ ,= purposes ( subsection 7a71 !   
t]m ,t-cell diagno/ic laboratory te/    
means a cl9ical laboratory te/ t is--   
7#a7 int5d$ to id5tify an adaptive      
,t-cell immune response to              
,,s>s-,co,v-#b indicative ( rec5t or    
prior infection ) ,,s>s-,co,v-#b2 &     
7#b7 cle>$1 approv$1 or o!rwise au?oriz$
 pursuant to ! ,f$]al ,food1 ,drug1 &   
,cosmetic ,act 7#ba ,u4,s4,c4 #cja et   
seq474  #d4 ,national /rategy =         
,,covid-#ai cellul> immune response     
rese>*  7a7 ,9 g5]al ,! ,secret>y (     
,heal? & ,human ,s]vices 79 ?is section 
ref]r$ to z ! ,secret>y7-- 7#a7 %all--  
7,a7 exp&1 int5sify1 & coord9ate !      
programs & activities ( ! ,national     
,in/itutes ( ,heal? & ! ,c5t]s =        
,disease ,control & ,prev5tion ) respect
 to sci5tific & cl9ical rese>* on !     

cellul> immune response relat$ to       
,,covid-#ai2  7,b7 develop & implem5t a 
national /rategy to rese>* ! cellul>    
immune response to ,,s>s-,co,v-#b1 :i*  
%all include rese>* on-- 7i7 ! type &   
duration ( ,t-cell responses to         
,,covid-#ai vacc9es & h[ su* responses  
conf] immunity & contribute to          
protection f infection ) ,,s>s-,co,v-#b 
v>iants ( conc]n2  7ii7 ! type &        
duration ( ,t-cell responses 9 pati5ts  
:o h recov]$ f ,,covid-#ai & h[ su*     
responses may conf] immunity2  7iii7 !  
type & duration ( ,t-cell immune        
responses 9 pati5ts fac+ long-t]m       
,,covid-#ai symptoms2 &  7iv7 ! type &  
duration ( ,t-cell responses to         
vacc9ation & natural infection 9 c]ta9  
populations1 su* z *ildr51 ! eld]ly1 &  
immunocompromis$ individuals2 &  7,c7   
update ! /rategy "u subp>agraph 7,b7 z  
appropriate2 &  7#b7 subject to !       
availability ( appropriations1 may make 
grants to ,/ates1 political             
subdivisions1 public-private p>tn]%ips1 

academic in/itutions1 & o!r public      
entities to c>ry out sci5tific & cl9ical
 rese>* on ! cellul> immune response    
relat$ to ,,covid-#ai & to implem5t !   
/rategy "u p>agraph 7#b74  7b7          
,consultation ,9 c>ry+ out subsection   
7a71 ! ,secret>y %all consult ) relevant
 individuals1 z appropriate1 su* z--    
7#a7 cl9icians1 public heal?            
pr(essionals1 & o!rs ) exp]tise 9       
cellul> immune response2  7#b7          
repres5tatives ( pati5t advocacy &      
rese>* organizations ) int]e/ 9 cellul> 
immune rese>*2  7#c7 rese>*]s ) exp]tise
 9 cellul> immunology2 &  7#d7          
epidemiologi/s ) exp]i5ce 9 cellul>     
immune response4  7c7 ,public meet+ ,n  
lat] ?an #c mon?s aft] ! date ( !       
enactm5t ( ?is ,act1 ! ,secret>y1 act+  
?r\gh ! ,director ( ! ,national         
,in/itutes ( ,heal?1 %all conv5e a      
public meet+ compos$ ( subject matt]    
exp]ts & /akehold]s to id5tify rese>*   
ne$s & opportunities4  7d7 ,publication 
( /rategy ,! ,secret>y %all make public 

! /rategy "u subsection 7a77#a77;,b71   
includ+ initial fund+ opportunity       
ann\ncem5ts1 )9 #f mon?s ( ! date (     
enactm5t ( ?is ,act4